The company has received final approval from the US Food and Drug Administration (USFDA) to manufacture and market Dexmedetomidine Hydrochloride in 0.9 per cent sodium chloride injection, 200 µg/50 mL and 400 µg/100 mL single dose flexible containers (bags), Aurobindo Pharma said in a regulatory filing.from Moneycontrol Business News https://ift.tt/3qI6ZPy
No comments:
Post a Comment